Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.
You may also be interested in...
Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.
Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval
Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.
Fujisawa Micafungin Safety, Prophylatic Use Could Be Benefits Vs. Cancidas
Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.